Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This medication can be a “boon”
Sound coming through perfect here.
How many times have I heard that throughout the years......
Just be patient and watch the game.
Queue the Armageddon quote “ ITS NOT A MATTER OF IF........BUT WHEN “
Shareholders would approve a measly $1B-$5B?
You say:
“Therefore, the only logical conclusion I can draw is that Biogen and big pharmas in CNS generally don’t think much of Anavex.”
I say:
“The only reason we haven’t been bought out yet is because we are not for sale.”
It’s much like a broken car. The owner would willingly sell/trade to a dealership if it is in the best interest of himself.
We don’t have a broken car. We have a car so futuristic, the world isn’t yet ready to believe what they see.
They soon will though and everyone will want one.
That’s one way to think of it.
Another is wash trading back and forth.
And BIIB used said $1.5B from that pump and dump of a FDA review BS
How else would BP continue to be BP. Gobbling up baby bio companies are their bread and butter. They don’t invent most of the poisons that get approved.
8 course meal.....
Why else would Missling have mentioned Shake it Up Foundation (Aug2020) in a separate PR? I thought P3 was a forgone conclusion.....
Medical Monitoring, Defined
Medical monitoring is an essential component of the clinical research process. Medical monitors provide medical expertise and oversight for the entire clinical trial, from initial study design through final study close-out. They ensure the clinical integrity of the trial subjects and provide safety accountability across the duration of the study, while acting as expert points of reference for both investigative sites and study team members.
https://www.c3isolutions.com/blog/medical-monitoring-101/
Don’t look here. This REALLY isn’t a giant golden nugget. If it was, do you think it would only cost $5 for a portion? We are BIG PHARMA. We know what to look for. Don’t listen to anyone else. Amaloid IS the way.......just wait and see.
Meanwhile......BP is drooling like a rabid dog hoping they can get their hands on Blarcamesine at a flash sale price.
Luckily for Anavex, the FDA isn’t the end all be all for the co. Getting approved in the EU or down under are options as well.
Just keeps on chugging....
I like this part.
•Differentiated clinical-stage CNS assets targeting significant and growing markets
• Patent protection to 2030-2039, worldwide rights for all product candidates
Pretty sure it’s something he learned over the years. PRs can be a good thing, but for Anavex it has been used against them. “PR machine” from years past come to mind.
Approval in Rett = BP. Watch the dots just magically connect. If it’s good for Rett, and it’s safe and benefits the PDD group, let’s just off-label it for PDD.....Hey, why not the AD groups too.
Insomnia......depression....ahhh.....
It’s time to see what we have in A-371
ALL MY OWN OPINION
Curious if THAT is why BIIB brought aducanumab back from the dead. It failed in March 2019. Hampel got hired by Eisai in May 2019. aducanumab mysteriously returns from the dead October 2019.
So could Eisai be ready to partner now that they’ve been fooled twice? Or will it take 3 times before they are through with BIIB and it’s lies and start looking for “new” potential for CNS diseases.
Dr. Hampel: sir, I’ve been on board with Anavex and we should take a serious look at Anavex.
Pop the champagne
Looks like BIIB will have to defend itself from a class action
https://apple.news/AX5UitrH2S8uKXfhdmoBE0w
“You are absolutely correct, they will keep looking. There really is no choice.”
In my opinion, I believe Biogen already knows what they want. They were trying to play the long game and have Anavex have a slow death. Snuffing out funding and presenting FUD every time Anavex had anything relevant to present.
Really believe if Anavex was for sale, they would have wasted $75 million on a drug from Pfizer? Of course Millions and Billions are way different.
“Biogen said it will also develop PF-05251749 for irregular sleep-wake rhythm disorder in Parkinson’s disease.”
Hmmm..... wasn’t there a line from ctad that discussed sleep. Guess we beat them to the punch again.
Make no mistake, we hit the wine glass on the dinner table and have everyone’s attention.
You DO know what the primary endpoint was, don’t you?
Oh no, the news from last week......
Right?
If BIIB can end a p3, call it a failure, and still manipulate data to show SOME type of positive on 2 trial but not the other.......Then still think it’ll get approved. Imagine a company that HAS successful endpoints, SHOWS that it’s better than soc, and only side effects are headaches? Oh, and by the way I’ll give you 3 years of data after end of trial on top of everything else.
We all know what happened when Netflix pitched itself to blockbuster.....
Nope.
Bottom line is BIIB still has lipstick on a pig.
Anavex possibly could have Blarcamesine denied for Alzheimer’s. Lucky for them, it isn’t a one hit wonder.
Did you mention that to BIIB? They sure thought it was
So if he were to get the data on both candidates, which one do you think he would take? Data being what’s available from BIIB and Anavex currently.
Yes Bas,
typical look at what I got in this hand(Paid articles of how BIIB will get favorable reviews today) , while the real show is in the other hand.(taking attention away from a REAL cns candidate)
What will BIIB do when the pdd data gets released, or when Rett results/data gets released, or dots connecting how certain cns diseases are similar, or.......
You get the point.
Biogen can only pump that failure so much times and time IS running out for them.
Next time we hear about Biogen and Alzheimer’s should now be what....., March?
Curious where Anavex will be trials wise.
Well, if you look at how much BIIB gained over the past 2 days.....that is a lot of funds that could easily prop up or bring down their competition. Especially ones with a small MC. Not saying that is what happened.
Next week we shall see if any of the insiders that knew Biogen wouldn’t get favorable news and sold during the pump.....will buy AVXL on the cheap.
Poor BIIB bag holders that bought on the run up.
I bet buffet is out of his BIIB shares. Any takers
With Rett results lurking in the background.....
What I’ve noticed about the board over the years is that there’s over expectation as far as what is actually released. Then after the fact the criticisms begin.
Just kick back, relax, and let Missling execute his vision.
Can’t stand playing the long game........there’s a ton more get rich quick schemes.
It’s been 5 years since Anavex rang the closing bell, or was it the opening......?
THEY called it quits. IT failed. Doesn’t matter how many people were enrolled. They should have to confirm their fake positivity found but we’ll see what deep pockets can buy tomorrow.
So simple when you analyze after failure right.
Could you imagine if Anavex tried that.....the crap the Cramers or Adams of the world would give them.
I was saying as of Nov 2, they are still scheduled to present on Nov 6 @ 11am. So they haven’t been pulled for some made up reasoning ppl may come up with.
https://www.ctad-alzheimer.com/files/files/DIGITALprogram_CTAD2020_23oct.pdf
They are in the program as of Oct 23
LB25 - ANAVEX®2-73 (blarcamesine) Currently in Phase 2b/3 Early Alzheimer’s Disease (AD): Analysis of Cognitive Outcome Measures Relevant in AD of Double-blind, Multicenter, Placebo-controlled Phase 2 Clinical Trial in 132 Patients with Parkinson’s Disease Dementia
Dag Aarsland (1), Jaime Kulisevsky Bojarski (2), Mohammad Afshar (3), Coralie Williams (3), Frederic Parmentier (3), Martin
(1)King’s College - London (United Kingdom); (2)University of Barcelona - Barcelona (Spain); (3)Ariana Pharma - Paris (France); (4)Anavex Life Sciences - New York, NY (United States)
Kindermans (3), Tayo Fadiran (4), Andy Mattai (4), Christopher U Missling (4), Walter E Kaufmann (4)
https://www.ctad-alzheimer.com/files/files/DIGITALprogram_CTAD2020_23oct.pdf
No one seems to think it a coincidence Anavex got a slot for LB at CTAD after BIIB will go to the FDA advisory meeting to discuss the BLA within hours of each other with their joke of a candidate?
Last year it was BIIB lying to steal Anavex thunder.........
This year......
What’s the time difference?
And if BIIB gets their candidate approved next month?
COVID-19 Might Increase Risk of Memory Loss and Cognitive Decline
https://www.discovermagazine.com/health/how-covid-19-might-increase-risk-of-memory-loss-and-cognitive-decline
If A-273 does get approved for any indication, what’s the chances of doctors prescribing a-273 for the above?
What other treatment plans is there for neurological damage covid leaves behind.
Another dot connected. How long ago was it that the topic of the day on the board was the gut?
https://www.yahoo.com/news/researchers-study-between-gut-health-213618194.html